STOCK TITAN

Septerna Board Member Gets Performance-Linked Stock Package Worth $170K

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Director Jeffrey K. Tong of Septerna received a stock option grant on June 17, 2025, representing a significant insider transaction. The details include:

  • Granted 16,623 stock options to purchase common stock
  • Exercise price set at $10.24 per share
  • Options expire on June 16, 2035
  • Vesting schedule: 100% vests upon earlier of June 17, 2026 or next annual stockholder meeting
  • Vesting conditional on continued service with company

This Form 4 filing represents a standard director compensation arrangement through equity incentives, aligning the director's interests with shareholders. The one-year cliff vesting structure suggests a retention mechanism while promoting long-term value creation.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tong Jeffrey K

(Last) (First) (Middle)
C/O SEPTERNA, INC.
250 EAST GRAND AVENUE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.24 06/17/2025 A 16,623 (1) 06/16/2035 Common Stock 16,623 $0 16,623 D
Explanation of Responses:
1. The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
/s/ Jeffrey Finer, Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did Jeffrey K. Tong receive from SEPN on June 17, 2025?

Jeffrey K. Tong received 16,623 stock options (right to buy) from Septerna, Inc. (SEPN) on June 17, 2025, with an exercise price of $10.24 per share.

What is the vesting schedule for SEPN director Jeffrey Tong's June 2025 stock options?

The stock options will vest in full upon the earlier of (i) June 17, 2026 or (ii) Septerna's next annual meeting of stockholders, subject to Jeffrey Tong's continued service to the company through the vesting date.

When do Jeffrey Tong's SEPN stock options expire?

The stock options granted to Jeffrey K. Tong expire on June 16, 2035, ten years after the grant date.

What is Jeffrey K. Tong's role at SEPN according to the Form 4?

According to the Form 4 filing, Jeffrey K. Tong serves as a Director of Septerna, Inc. (SEPN), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What was the exercise price of SEPN stock options granted to Jeffrey Tong in June 2025?

The exercise price (conversion price) of the stock options granted to Jeffrey Tong was $10.24 per share.
Septerna, Inc.

NASDAQ:SEPN

SEPN Rankings

SEPN Latest News

SEPN Latest SEC Filings

SEPN Stock Data

1.23B
42.93M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO